Price T Rowe Associates Inc Neurocrine Biosciences Inc Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
625Shares Held
95.2MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.65 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.17 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$535 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$287 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$275 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...